The combination treatment with GB1211 and a blocking anti-PD-L1 monoclonal antibody reduced tumor growth in an LLC1 syngeneic mouse lung cancer model, which was accompanied by an increased percentage of CD8+ TILs [163] (Table 1). Here, CD8A is linked to neoplasm.